Anil Parwani, MD, PhD, discusses how he sees artificial intelligence technology contributing to personalized medicine and helping to tailor treatment plans for individual patients in the future.
Anil Parwani, MD, PhD, professor of pathology at The Ohio State University Wexner Medical Center, discusses how he sees artificial intelligence (AI) technology contributing to personalized medicine and helping to tailor treatment plans for individual patients in the future.
Parwani explains that AI tools are set to propel cancer care forward by providing precise diagnoses and treatment predictions. These will integrate various patient factors to move from personalized to precision medicine.
Transcription:
0:09 | Just like I mentioned, there are many patients whose prostate cancer looks the same, but they are very different in their outcomes, they are very different in how the cancer progresses. There are other factors in the cancer, the tumor microenvironment, or the patient's demographics, or their background, or their family history. Through building the AI tools, which are predictive and comprehensive, they can pinpoint which patient will benefit from this therapy or not. We think about personalized medicine, but I think about precision. I think that precision diagnosis leads to precision medicine, and AI will help us get to the precise diagnosis, and help us create a bridge from just a diagnosis to a more powerful profile of the patient.
1:12 | That is where I think this is headed towards and I can start to see this. When I went to medical school and when I was a resident, I did not even think that we would come to a point where I would be looking at a monitor and looking at signatures of cancer and how they will respond to treatments. My role as a pathologist has evolved completely now because I am not somebody who is just making a diagnosis. I am part of the whole patient care team now and I am part of this process, which will help oncologists get a better and more precise diagnosis for their patients, which will lead to a more precise treatment for them.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More